1. Phylogeny  
   Tyrosine‐protein kinase JAK2 belongs to the Janus kinase (JAK) family, a group of non‐receptor tyrosine kinases that also includes JAK1, JAK3, and TYK2. This family is evolutionarily conserved among metazoans and plays a pivotal role in cytokine receptor signaling. JAK2 shares a conserved domain architecture with its relatives, which includes an N‐terminal FERM domain, an SH2-like domain, a pseudokinase (JH2) domain, and a catalytic kinase (JH1) domain; this arrangement is retained in orthologs across a wide range of species, from model vertebrates to humans (downes2022jak2alterationsin pages 2-4, glassman2022structureofa pages 1-3). In the kinome group, JAK2 is classified within the receptor-associated tyrosine kinases and is part of a core set of signaling proteins that mediate cytokine responses—a function so critical that its evolutionary conservation suggests an origin dating back to the last common ancestor of vertebrates (hammaren2019januskinase2 pages 1-2).
2. Reaction Catalyzed  
   JAK2 catalyzes a classic protein tyrosine kinase reaction. The reaction involves the binding of ATP to the kinase (JH1) domain of JAK2, where the γ-phosphate of ATP is transferred to the hydroxyl group of a specific tyrosine residue on a substrate protein. Physiologically, the substrates of this reaction include tyrosine residues present on the intracellular domains of cytokine receptors as well as on downstream signaling molecules such as the STAT (signal transducers and activators of transcription) proteins. The transfer reaction can be summarized as:  
     ATP + protein–tyrosine → ADP + protein–phosphotyrosine  
   Phosphorylation by JAK2 is both autophosphorylating (on its own activation loop tyrosines) and trans-phosphorylating (on associated receptor chains and recruited signaling proteins), thereby triggering cascades such as the JAK/STAT pathway (downes2022jak2alterationsin pages 4-6, downes2022jak2alterationsin pages 6-7, glassman2022structureofa pages 9-11). Although detailed atomic-level reaction mechanisms remain under investigation, the fundamental catalytic process follows the conventional mechanism observed in tyrosine kinases—requiring precise alignment of the ATP γ-phosphate with the substrate’s tyrosyl hydroxyl group for effective nucleophilic attack (abraham2024molecularbasisof pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of JAK2, consistent with typical kinases, depends on divalent metal ions. In general, Mg²⁺ ions are required to coordinate with ATP in the active site, stabilizing the negative charges on the phosphate groups and facilitating the transfer of the γ-phosphate during the phosphorylation process. Although explicit experimental details for JAK2 are not exhaustively provided in every study, its reaction mechanism and structural analysis strongly indicate that Mg²⁺ is an essential cofactor (abraham2024molecularbasisof pages 11-12, glassman2022structureofa pages 4-6).
4. Substrate Specificity  
   JAK2 demonstrates substrate specificity in its phosphorylation reactions that is critical for proper signal transduction. Physiologically, its primary substrates include:  
    – Cytokine receptor intracellular domains  
    – STAT transcription factors (e.g., STAT5A, STAT5B, STAT3)  
   In addition, reports suggest that JAK2 can phosphorylate other substrates involved in cell cycle regulation (such as CDKN1B) and even histone H3 on Tyr-41 in the nucleus, affecting chromatin structure (Information section). The enzyme recognizes substrates through a combination of sequence and structural motifs; although a simple linear consensus motif has not been universally defined, the presence of accessible tyrosine residues in a docking region near cytokine receptor Box1/Box2 motifs appears essential (downes2022jak2alterationsin pages 4-6, glassman2022structureofa pages 9-11, hammaren2019januskinase2 pages 10-11). Several studies emphasize that substrate binding is largely determined by the spatial arrangement provided by receptor dimerization—thus promoting the proximity of JAK2 to specific tyrosine clusters on the receptor tails (jin2018jakandstat pages 6-10).
5. Structure  
   JAK2 is composed of multiple domains that each contribute to its overall function. Its N-terminal region contains a FERM domain that mediates binding to cytokine receptors via conserved Box1 and Box2 motifs in the receptor’s intracellular juxtamembrane region (downes2022jak2alterationsin pages 2-4, ferrao2018receptormediateddimerizationof pages 1-2). This domain is followed by an SH2-like domain, which further supports protein-protein interactions. Centrally located is the pseudokinase (JH2) domain, which lacks full catalytic activity but plays a key regulatory role by maintaining JAK2 in an autoinhibited conformation in resting cells. Importantly, mutations in the pseudokinase domain, such as the well-known V617F mutation, can disrupt this autoinhibition and lead to constitutive activation (downes2022jak2alterationsin pages 4-6, hammaren2019januskinase2 pages 1-2). The C-terminal kinase (JH1) domain houses the active site responsible for ATP binding and the ensuing phosphotransfer reaction. High-resolution structures, including those derived from cryo-electron microscopy and crystallographic studies, have revealed that upon cytokine binding and receptor dimerization, significant conformational changes occur in the kinase domain to adopt an active “DFG-in” configuration. This rearrangement properly aligns catalytic residues, such as the properly oriented glutamate in the N-lobe αC helix, to facilitate the transfer of the phosphate group (glassman2022structureofa pages 4-6, glassman2022structureofa pages 8-9). Together, the modular organization of JAK2 underpins its ability to switch between inactive and active conformations in response to external signals.
6. Regulation  
   The activity of JAK2 is tightly regulated by multiple overlapping mechanisms. Under basal conditions, the pseudokinase (JH2) domain exerts an autoinhibitory effect on the kinase domain (JH1), maintaining low levels of activity. Upon cytokine engagement of receptors such as EPOR, GHR, MPL, or LEPR, receptor dimerization brings two JAK2 molecules into proximity, enabling trans-phosphorylation of activation loop tyrosines (e.g., Tyr1007/Tyr1008) in the JH1 domain; this is a critical step in full kinase activation (downes2022jak2alterationsin pages 4-6, glassman2022structureofa pages 3-4, hammaren2019januskinase2 pages 8-10). Additionally, regulatory proteins such as suppressors of cytokine signaling (SOCS1 and SOCS3) and protein tyrosine phosphatases (e.g., SHP-2) actively modulate JAK2 signaling by dephosphorylating the receptor complexes or JAK2 itself, thereby terminating the signal (gorantla2025ruxolitinibmediatedparadoxical pages 2-3, hammaren2019januskinase2 pages 2-2). Moreover, small-molecule inhibitors like ruxolitinib bind competitively at the ATP-binding pocket in the active conformation of JAK2, inhibiting its catalytic function; however, paradoxically, some inhibitors can also lead to increased phosphorylation of the activation loop by protecting these residues from dephosphorylation (gorantla2025ruxolitinibmediatedparadoxical pages 2-3, vainchenker2018jakinhibitorsfor pages 6-7). Thus, JAK2 regulation is a balance between autoinhibitory intramolecular interactions, receptor-mediated dimerization and activation, and extrinsic regulatory processes mediated by phosphatases and inhibitory proteins.
7. Function  
   JAK2 is a central mediator of cytokine signaling in both innate and adaptive immunity and is critical for hematopoiesis, cell growth, differentiation, and survival. In the cytoplasm, following cytokine binding to receptors—such as erythropoietin receptor (EPOR), thrombopoietin receptor (MPL/TPOR), growth hormone receptor (GHR), prolactin receptor (PRLR), and leptin receptor (LEPR)—JAK2 is activated via trans-phosphorylation and subsequently phosphorylates specific tyrosine residues on the receptor cytoplasmic domains. These phosphorylated tyrosines serve as docking sites for STAT proteins, which are then phosphorylated by JAK2, dimerize, and translocate into the nucleus to drive gene transcription programs pivotal in processes such as erythropoiesis, immune regulation, and metabolism (downes2022jak2alterationsin pages 2-4, lin2018anovelselective pages 1-2). In addition to its canonical role in the JAK/STAT pathway, JAK2 has been reported to phosphorylate nuclear substrates; for example, it specifically mediates the phosphorylation of histone H3 at Tyr-41, a modification that modulates chromatin structure through exclusion of heterochromatin protein CBX5 (HP1α), thereby influencing transcriptional regulation (Information section, abraham2024molecularbasisof pages 13-14). JAK2 also contributes to cell cycle regulation and may collaborate with other kinases like TEC in reciprocal phosphorylation events that modulate transcription factor activity (Information section). Through these diverse roles, JAK2 integrates extracellular cytokine signals with intracellular responses that govern cell proliferation, differentiation, immunity, and even metabolic pathways.
8. Other Comments  
   Beyond its fundamental biological functions, aberrant JAK2 activity is implicated in several hematological disorders, including myeloproliferative neoplasms (MPNs) and certain forms of acute lymphoblastic leukemia (ALL). The most striking example is the V617F mutation in the pseudokinase domain, which leads to constitutive kinase activation and ligand-independent signaling, ultimately driving pathological proliferation (downes2022jak2alterationsin pages 4-6, hammaren2019januskinase2 pages 1-2). This constitutive activation has spurred the development of JAK inhibitors such as ruxolitinib and fedratinib, which are clinically employed to modulate JAK2 activity; however, challenges remain regarding the specificity and paradoxical regulatory effects of these inhibitors (vainchenker2018jakinhibitorsfor pages 6-7, gorantla2025ruxolitinibmediatedparadoxical pages 2-3). Furthermore, recent structural studies have illuminated the precise molecular architecture underlying JAK2 activation and regulation, presenting new opportunities for the design of allosteric modulators that might better discriminate between pathological and normal signaling states (glassman2022structureofa pages 4-6, ferrao2018receptormediateddimerizationof pages 21-21). Ongoing research is also exploring the non-canonical roles of JAK2 within the nucleus, particularly concerning chromatin modification and transcriptional regulation—a function that expands the therapeutic implications of targeting this kinase in both oncology and immune-mediated disorders (abraham2024molecularbasisof pages 13-14).
9. References  
   [References will be compiled and formatted according to the publication standards using the provided citation keys.]

References

1. (downes2022jak2alterationsin pages 4-6): Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung, and Deborah L. White. Jak2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies. Frontiers in Cell and Developmental Biology, Jul 2022. URL: https://doi.org/10.3389/fcell.2022.942053, doi:10.3389/fcell.2022.942053. This article has 31 citations and is from a peer-reviewed journal.
2. (downes2022jak2alterationsin pages 6-7): Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung, and Deborah L. White. Jak2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies. Frontiers in Cell and Developmental Biology, Jul 2022. URL: https://doi.org/10.3389/fcell.2022.942053, doi:10.3389/fcell.2022.942053. This article has 31 citations and is from a peer-reviewed journal.
3. (glassman2022structureofa pages 9-11): Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, Patrick J. Lupardus, Kevin M. Jude, and K. Christopher Garcia. Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376:163-169, Apr 2022. URL: https://doi.org/10.1126/science.abn8933, doi:10.1126/science.abn8933. This article has 123 citations and is from a highest quality peer-reviewed journal.
4. (abraham2024molecularbasisof pages 1-2): Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T. Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, and Olli Silvennoinen. Molecular basis of jak2 activation in erythropoietin receptor and pathogenic jak2 signaling. Science Advances, Mar 2024. URL: https://doi.org/10.1126/sciadv.adl2097, doi:10.1126/sciadv.adl2097. This article has 5 citations and is from a highest quality peer-reviewed journal.
5. (abraham2024molecularbasisof pages 11-12): Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T. Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, and Olli Silvennoinen. Molecular basis of jak2 activation in erythropoietin receptor and pathogenic jak2 signaling. Science Advances, Mar 2024. URL: https://doi.org/10.1126/sciadv.adl2097, doi:10.1126/sciadv.adl2097. This article has 5 citations and is from a highest quality peer-reviewed journal.
6. (abraham2024molecularbasisof pages 13-14): Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T. Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, and Olli Silvennoinen. Molecular basis of jak2 activation in erythropoietin receptor and pathogenic jak2 signaling. Science Advances, Mar 2024. URL: https://doi.org/10.1126/sciadv.adl2097, doi:10.1126/sciadv.adl2097. This article has 5 citations and is from a highest quality peer-reviewed journal.
7. (downes2022jak2alterationsin pages 2-4): Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung, and Deborah L. White. Jak2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies. Frontiers in Cell and Developmental Biology, Jul 2022. URL: https://doi.org/10.3389/fcell.2022.942053, doi:10.3389/fcell.2022.942053. This article has 31 citations and is from a peer-reviewed journal.
8. (glassman2022structureofa pages 1-3): Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, Patrick J. Lupardus, Kevin M. Jude, and K. Christopher Garcia. Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376:163-169, Apr 2022. URL: https://doi.org/10.1126/science.abn8933, doi:10.1126/science.abn8933. This article has 123 citations and is from a highest quality peer-reviewed journal.
9. (glassman2022structureofa pages 3-4): Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, Patrick J. Lupardus, Kevin M. Jude, and K. Christopher Garcia. Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376:163-169, Apr 2022. URL: https://doi.org/10.1126/science.abn8933, doi:10.1126/science.abn8933. This article has 123 citations and is from a highest quality peer-reviewed journal.
10. (hammaren2019januskinase2 pages 1-2): Henrik M. Hammarén, Anniina T. Virtanen, Bobin George Abraham, Heidi Peussa, Stevan R. Hubbard, and Olli Silvennoinen. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. Journal of Allergy and Clinical Immunology, 143:1549-1559.e6, Apr 2019. URL: https://doi.org/10.1016/j.jaci.2018.07.022, doi:10.1016/j.jaci.2018.07.022. This article has 31 citations and is from a highest quality peer-reviewed journal.
11. (hammaren2019januskinase2 pages 10-11): Henrik M. Hammarén, Anniina T. Virtanen, Bobin George Abraham, Heidi Peussa, Stevan R. Hubbard, and Olli Silvennoinen. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. Journal of Allergy and Clinical Immunology, 143:1549-1559.e6, Apr 2019. URL: https://doi.org/10.1016/j.jaci.2018.07.022, doi:10.1016/j.jaci.2018.07.022. This article has 31 citations and is from a highest quality peer-reviewed journal.
12. (hammaren2019januskinase2 pages 2-2): Henrik M. Hammarén, Anniina T. Virtanen, Bobin George Abraham, Heidi Peussa, Stevan R. Hubbard, and Olli Silvennoinen. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. Journal of Allergy and Clinical Immunology, 143:1549-1559.e6, Apr 2019. URL: https://doi.org/10.1016/j.jaci.2018.07.022, doi:10.1016/j.jaci.2018.07.022. This article has 31 citations and is from a highest quality peer-reviewed journal.
13. (hammaren2019januskinase2 pages 8-10): Henrik M. Hammarén, Anniina T. Virtanen, Bobin George Abraham, Heidi Peussa, Stevan R. Hubbard, and Olli Silvennoinen. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. Journal of Allergy and Clinical Immunology, 143:1549-1559.e6, Apr 2019. URL: https://doi.org/10.1016/j.jaci.2018.07.022, doi:10.1016/j.jaci.2018.07.022. This article has 31 citations and is from a highest quality peer-reviewed journal.
14. (jin2018jakandstat pages 6-10): Yulin Jin, Tao Zhou, Ning Li, Shikai Liu, Xiaoyan Xu, Ying Pan, Suxu Tan, Huitong Shi, Yujia Yang, Zihao Yuan, Wenwen Wang, Jian Luo, Dongya Gao, Rex Dunham, and Zhanjiang Liu. Jak and stat members in channel catfish: identification, phylogenetic analysis and expression profiling after edwardsiella ictaluri infection. Developmental & Comparative Immunology, 81:334-341, Apr 2018. URL: https://doi.org/10.1016/j.dci.2017.12.019, doi:10.1016/j.dci.2017.12.019. This article has 38 citations.
15. (vainchenker2018jakinhibitorsfor pages 6-7): William Vainchenker, Emilie Leroy, Laure Gilles, Caroline Marty, Isabelle Plo, and Stefan N. Constantinescu. Jak inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research, 7:82, Jan 2018. URL: https://doi.org/10.12688/f1000research.13167.1, doi:10.12688/f1000research.13167.1. This article has 173 citations and is from a peer-reviewed journal.
16. (ferrao2018receptormediateddimerizationof pages 1-2): Ryan D Ferrao, Heidi JA Wallweber, and Patrick J Lupardus. Receptor-mediated dimerization of jak2 ferm domains is required for jak2 activation. eLife, Jul 2018. URL: https://doi.org/10.7554/elife.38089, doi:10.7554/elife.38089. This article has 62 citations and is from a domain leading peer-reviewed journal.
17. (ferrao2018receptormediateddimerizationof pages 21-21): Ryan D Ferrao, Heidi JA Wallweber, and Patrick J Lupardus. Receptor-mediated dimerization of jak2 ferm domains is required for jak2 activation. eLife, Jul 2018. URL: https://doi.org/10.7554/elife.38089, doi:10.7554/elife.38089. This article has 62 citations and is from a domain leading peer-reviewed journal.
18. (glassman2022structureofa pages 4-6): Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, Patrick J. Lupardus, Kevin M. Jude, and K. Christopher Garcia. Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376:163-169, Apr 2022. URL: https://doi.org/10.1126/science.abn8933, doi:10.1126/science.abn8933. This article has 123 citations and is from a highest quality peer-reviewed journal.
19. (glassman2022structureofa pages 8-9): Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, Patrick J. Lupardus, Kevin M. Jude, and K. Christopher Garcia. Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376:163-169, Apr 2022. URL: https://doi.org/10.1126/science.abn8933, doi:10.1126/science.abn8933. This article has 123 citations and is from a highest quality peer-reviewed journal.
20. (gorantla2025ruxolitinibmediatedparadoxical pages 2-3): Sivahari P. Gorantla, Lorenz Oelschläger, Gerin Prince, Jasmin Osius, Suresh Babu Kolluri, Yamil Maluje, Anke Fähnrich, Nancy Ernst, Alanis Barbosa Gulde, Ralf Joachim Ludwig, Timo Gemoll, Stephanie Fliedner, Wencke Walter, Torsten Haferlach, Niklas Gebauer, Hauke Busch, Justus Duyster, and Nikolas von Bubnoff. Ruxolitinib mediated paradoxical jak2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases. Leukemia, Apr 2025. URL: https://doi.org/10.1038/s41375-025-02594-7, doi:10.1038/s41375-025-02594-7. This article has 0 citations and is from a highest quality peer-reviewed journal.
21. (lin2018anovelselective pages 1-2): Tony Eight Lin, Wei-Chun HuangFu, Min-Wu Chao, Tzu-Ying Sung, Chao-Di Chang, Yi-Ying Chen, Jui-Hua Hsieh, Huang-Ju Tu, Han-Li Huang, Shiow-Lin Pan, and Kai-Cheng Hsu. A novel selective jak2 inhibitor identified using pharmacological interactions. Frontiers in Pharmacology, Dec 2018. URL: https://doi.org/10.3389/fphar.2018.01379, doi:10.3389/fphar.2018.01379. This article has 31 citations and is from a peer-reviewed journal.